TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

Cancer Cell

Volumn 33, Issue 1, 2018, Pages 60-74.e6

  de Mingo Pulido, Álvaro ^a   Gardner, Alycia ^a,b   Hiebler, Shandi ^a   Soliman, Hatem ^a   Rugo, Hope S ^c   Krummel, Matthew F ^c   Coussens, Lisa M ^d   Ruffell, Brian ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

breast cancer; chemotherapy; dendritic cells; galectin 9; immunotherapy; paclitaxel; TIM 3

Indexed keywords

BATF3 PROTEIN; CD103 ANTIGEN; CD135 ANTIGEN; CD163 ANTIGEN; CXCL9 CHEMOKINE; CYTOKERATIN; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; FINGOLIMOD; GAMMA INTERFERON; GRANZYME B; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; ALPHA E INTEGRINS; ALPHA INTEGRIN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; HAVCR2 PROTEIN, HUMAN; HAVCR2 PROTEIN, MOUSE; INTERFERON REGULATORY FACTOR; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL SUSPENSION; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE; GENE EXPRESSION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOREGULATION; LUMINAL B BREAST CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; UPREGULATION; ANIMAL; BREAST TUMOR; CD4+ T LYMPHOCYTE; DEFICIENCY; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; INTEGRIN ALPHA CHAINS; INTERFERON REGULATORY FACTORS; MICE, TRANSGENIC;

EID: 85042419062     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.11.019     Document Type: Article

References (66)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. Anderson, A.C., Anderson, D.E., Bregoli, L., Hastings, W.D., Kassam, N., Lei, C., Chandwaskar, R., Karman, J., Su, E.W., Hirashima, M., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318 (2007), 1141–1143.
3. Anderson, A.C., Joller, N., Kuchroo, V.K., Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44 (2016), 989–1004.
4. Baghdadi, M., Nagao, H., Yoshiyama, H., Akiba, H., Yagita, H., Dosaka-Akita, H., Jinushi, M., Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol. Immunother. 62 (2013), 629–637.
5. + T cells in metastases from melanoma patients. J. Clin. Invest. 121 (2011), 2350–2360.
6. Bos, P.D., Plitas, G., Rudra, D., Lee, S.Y., Rudensky, A.Y., Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 210 (2013), 2435–2466.
7. Broz, M.L., Binnewies, M., Boldajipour, B., Nelson, A.E., Pollack, J.L., Erle, D.J., Barczak, A., Rosenblum, M.D., Daud, A., Barber, D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26 (2014), 638–652.
8. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
9. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
10. Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J.V., Colgan, J.D., et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13 (2012), 832–842.
11. Coffelt, S.B., de Visser, K.E., Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 36 (2015), 198–216.
12. DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden, S.F., Gallagher, W.M., Wadhwani, N., Keil, S.D., Junaid, S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1 (2011), 54–67.
13. + pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J. Exp. Med. 208 (2011), 1789–1797.
14. Engelhardt, J.J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., Krummel, M.F., Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21 (2012), 402–417.
15. + T cell dysfunction in melanoma patients. J. Exp. Med. 207 (2010), 2175–2186.
16. Fridman, W.H., Pages, F., Sautes-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.
17. Gorman, J.V., Starbeck-Miller, G., Pham, N.L., Traver, G.L., Rothman, P.B., Harty, J.T., Colgan, J.D., Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection. J. Immunol. 192 (2014), 3133–3142.
18. Grajales-Reyes, G.E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., Kc, W., Kretzer, N.M., Briseno, C.G., Durai, V., Bagadia, P., et al. Batf3 maintains autoactivation of Irf8 for commitment of a CD8α(+) conventional DC clonogenic progenitor. Nat. Immunol. 16 (2015), 708–717.
19. Guy, C.T., Cardiff, R.D., Muller, W.J., Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell Biol 12 (1992), 954–961.
20. Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., Szallasi, Z., An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123 (2010), 725–731.
21. Headley, M.B., Bins, A., Nip, A., Roberts, E.W., Looney, M.R., Gerard, A., Krummel, M.F., Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 531 (2016), 513–517.
22. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
23. Hess, K.R., Anderson, K., Symmans, W.F., Valero, V., Ibrahim, N., Mejia, J.A., Booser, D., Theriault, R.L., Buzdar, A.U., Dempsey, P.J., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24 (2006), 4236–4244.
24. + dendritic cells in cytotoxic T cell immunity. Science 322 (2008), 1097–1100.
25. Iijima, N., Iwasaki, A., T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science 346 (2014), 93–98.
26. + dendritic cell lineages. EMBO J. 30 (2011), 2690–2704.
27. Jin, H.T., Anderson, A.C., Tan, W.G., West, E.E., Ha, S.J., Araki, K., Freeman, G.J., Kuchroo, V.K., Ahmed, R., Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA 107 (2010), 14733–14738.
28. Jones, R.B., Ndhlovu, L.C., Barbour, J.D., Sheth, P.M., Jha, A.R., Long, B.R., Wong, J.C., Satkunarajah, M., Schweneker, M., Chapman, J.M., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205 (2008), 2763–2779.
29. Kane, L.P., T cell Ig and mucin domain proteins and immunity. J. Immunol. 184 (2010), 2743–2749.
30. Kanzaki, M., Wada, J., Sugiyama, K., Nakatsuka, A., Teshigawara, S., Murakami, K., Inoue, K., Terami, T., Katayama, A., Eguchi, J., et al. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology 153 (2012), 612–620.
31. + T cell responses in the lymph node. Immunity 38 (2013), 502–513.
32. Katoh, S., Ishii, N., Nobumoto, A., Takeshita, K., Dai, S.Y., Shinonaga, R., Niki, T., Nishi, N., Tominaga, A., Yamauchi, A., Hirashima, M., Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am. J. Respir. Crit. Care Med. 176 (2007), 27–35.
33. Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L., Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31 (2013), 51–72.
34. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
35. Lee, J., Su, E.W., Zhu, C., Hainline, S., Phuah, J., Moroco, J.A., Smithgall, T.E., Kuchroo, V.K., Kane, L.P., Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol. Cell Biol 31 (2011), 3963–3974.
36. Leitner, J., Rieger, A., Pickl, W.F., Zlabinger, G., Grabmeier-Pfistershammer, K., Steinberger, P., TIM-3 does not act as a receptor for galectin-9. PLoS Pathog., 9, 2013, e1003253.
37. Maroulakou, I.G., Anver, M., Garrett, L., Green, J.E., Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 91 (1994), 11236–11240.
38. Maurya, N., Gujar, R., Gupta, M., Yadav, V., Verma, S., Sen, P., Immunoregulation of dendritic cells by the receptor T cell Ig and mucin protein-3 via Bruton's tyrosine kinase and c-Src. J. Immunol. 193 (2014), 3417–3425.
39. Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E.A., Coyle, A.J., Sobel, R.A., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415 (2002), 536–541.
40. Nakayama, M., Akiba, H., Takeda, K., Kojima, Y., Hashiguchi, M., Azuma, M., Yagita, H., Okumura, K., Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113 (2009), 3821–3830.
41. Natsuaki, Y., Egawa, G., Nakamizo, S., Ono, S., Hanakawa, S., Okada, T., Kusuba, N., Otsuka, A., Kitoh, A., Honda, T., et al. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat. Immunol. 15 (2014), 1064–1069.
42. Ngiow, S.F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M.W., Smyth, M.J., Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71 (2011), 3540–3551.
43. + T cells in murine acute graft-versus-host disease. J. Immunol. 177 (2006), 4281–4287.
44. Phong, B.L., Avery, L., Sumpter, T.L., Gorman, J.V., Watkins, S.C., Colgan, J.D., Kane, L.P., Tim-3 enhances FcepsilonRI-proximal signaling to modulate mast cell activation. J. Exp. Med. 212 (2015), 2289–2304.
45. Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E.A., Sobel, R.A., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Nat. Med. 18 (2012), 1394–1400.
46. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
47. Roberts, E.W., Broz, M.L., Binnewies, M., Headley, M.B., Nelson, A.E., Wolf, D.M., Kaisho, T., Bogunovic, D., Bhardwaj, N., Krummel, M.F., Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30 (2016), 324–336.
48. Ruffell, B., Au, A., Rugo, H.S., Esserman, L.J., Hwang, E.S., Coussens, L.M., Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. USA 109 (2012), 2796–2801.
49. + T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26 (2014), 623–637.
50. Rugo, H.S., Barry, W.T., Moreno-Aspitia, A., Lyss, A.P., Cirrincione, C., Leung, E., Mayer, E.L., Naughton, M., Toppmeyer, D., Carey, L.A., et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (alliance). J. Clin. Oncol. 33 (2015), 2361–2369.
51. Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., Anderson, A.C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207 (2010), 2187–2194.
52. Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F.L., Penault-Llorca, F., et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26 (2015), 259–271.
53. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44 (2016), 924–938.
54. Sanchez-Paulete, A.R., Cueto, F.J., Martinez-Lopez, M., Labiano, S., Morales-Kastresana, A., Rodriguez-Ruiz, M.E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M.A., Quetglas, J.I., et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 Monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6 (2015), 71–79.
55. + DCs can be induced in the absence of transcription factors Id2, Nfil3, and Batf3. Blood 121 (2013), 1574–1583.
56. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20 (2014), 1301–1309.
57. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
58. Spranger, S., Dai, D., Horton, B., Gajewski, T.F., Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31 (2017), 711–723.e4.
59. Su, E.W., Bi, S., Kane, L.P., Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 21 (2011), 1258–1265.
60. Tabchy, A., Valero, V., Vidaurre, T., Lluch, A., Gomez, H., Martin, M., Qi, Y., Barajas-Figueroa, L.J., Souchon, E., Coutant, C., et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin. Cancer Res. 16 (2010), 5351–5361.
61. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
62. Walser, T.C., Rifat, S., Ma, X., Kundu, N., Ward, C., Goloubeva, O., Johnson, M.G., Medina, J.C., Collins, T.L., Fulton, A.M., Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66 (2006), 7701–7707.
63. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Foppen, M.H., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
64. van de Weyer, P.S., Muehlfeit, M., Klose, C., Bonventre, J.V., Walz, G., Kuehn, E.W., A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem. Biophys. Res. Commun. 351 (2006), 571–576.
65. Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515 (2014), 572–576.
66. Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., Zheng, X.X., Strom, T.B., Kuchroo, V.K., The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6 (2005), 1245–1252.